Navigation Links
Sequenom Introduces iPLEX® ADME PGx Panel on MassARRAY® System
Date:10/4/2011

SAN DIEGO, Oct. 4, 2011 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the launch of its iPLEX ADME PGx panel developed to genotype polymorphisms in genes associated with drug absorption, distribution, metabolism, and excretion (ADME). This Research Use Only (RUO) panel contains a set of pre-designed single nucleotide polymorphisms (SNP), insertions and deletions (INDELS) and copy number variation (CNV) assays for use in the investigation of variants with demonstrated relevance to drug metabolism. After detection on the MassARRAY (RUO) system, the proprietary software solution is then used to score and qualify polymorphisms to create a unique haplotype report.

"Sequenom customers have been successful in developing assays for a wide variety of ADME biomarkers, and numerous high-impact studies have been published using Sequenom technology," said Michael Monko, Senior Vice President, Genetic Analysis. "The iPLEX ADME PGx panel should help scientists quickly and reliably screen samples for genotypes relevant to drug metabolism, speeding the discovery of relevant genotypic markers associated with specific drug treatments."

The iPLEX ADME PGx panel should enable the basic and translational research communities to rapidly and accurately investigate pharmacogenetic biomarkers associated with drug metabolism. The iPLEX ADME PGx panel enables the analysis of 192 polymorphisms across 36 pharmacogenetically relevant genes. The panel uses Sequenom's iPLEX Gold biochemistry together with specific ADME oligonucleotides. The PGx panel consists of 200 assays in 8 wells requiring 10 ng of input DNA per well from fresh or frozen whole blood or cells.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

Forward-Looking Statements  

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the anticipated use, performance and benefits of the iPLEX ADME PGx panel and its acceptance and use as a genotyping tool by basic and translational researchers for pharmacogenetic applications, and the Company's commitment to improving healthcare through revolutionary genetic analysis solutions, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use by customers of new products such as the iPLEX ADME PGx panel, the Company's ability to position itself for product launches and growth and develop and commercialize new technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms and panels, reliance upon the collaborative efforts of other parties, ongoing litigation involving the Company, the Company's financial position, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, and other risks detailed from time to time in the Company's Annual Report on Form 10-K for the year ended December 31, 2010 and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)


'/>"/>
SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
2. SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30
3. SEQUENOM Announces Launch of MassARRAY Compact 96 System
4. SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
5. Sequenom Appoints Two New Board Members
6. SEQUENOM Announces Partnership With GeneWorks for Sales & Marketing of MassARRAY Systems and Applications in Australia
7. Sequenom to Present at Two Financial Conferences in March
8. Sequenom to Present at Two Financial Conferences in September
9. Sequenom Announces Formation of Ophthalmology Clinical Advisory Board
10. Sequenom Announces Exercise in Full of Underwriters Option to Purchase Additional Shares
11. Sequenom Announces Publication Acceptance of Manuscript From Trisomy 21 R&D Verification Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 Cousins Properties (NYSE: ... the world,s leading biotechnology companies, has signed a 10-year, approximately ... Class A office asset located in the Westshore submarket of ... are thrilled that Amgen has chosen Corporate Center for their ... Larry Gellerstedt , president and chief executive officer of Cousins ...
(Date:3/27/2017)... , March 27, 2017  Perthera,s Chief Bioinformatics Officer ... Subha Madhavan , Ph.D., will be speaking at ... Panels. On Monday, March 27, 2017, she will be ... More Usable for Research and Care" (from 10:30 a.m. ... 2017, she will be a participant in the "Making ...
(Date:3/27/2017)... , March 27, 2017  Trovagene, Inc. (NASDAQ: TROV), ... Chief Executive Officer, Bill Welch , will be ... 2017 at 9:00 AM EDT at the Essex House ... Welch, and Chief Scientific Officer, Mark Erlander , ... during the conference.   The presentation will be ...
(Date:3/24/2017)... MOSCOW and ROCKVILLE, Md. ... portfolio company of Maxwell Biotech Venture Fund (MBVF), today ... of SQ109 added to the standard drug therapy regimen ... a new small molecule drug discovered by scientists at ... US National Institutes of Health. A ...
Breaking Biology Technology:
(Date:3/13/2017)... 2017 Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or ... individuals. (PRNewsFoto/Dermalog Identification Systems) ... "Face Matching" is the fastest software for biometric Face Matching on the market. ...
(Date:3/6/2017)... , March 6, 2017 ... sales technology, today announced Predictive Sales Coach TM ... infusing actionable sales intelligence into Salesforce. This unique ... enable their sales organizations with deep knowledge of ... allow for intelligent engagement. Predictive Sales Coach extends ...
(Date:3/1/2017)... March 1, 2017  Aware, Inc. (NASDAQ: AWRE), a ... Richard P. Moberg has resigned, effective March ... Chief Financial Officer and Treasurer of Aware citing a ... as a member of the Board of Directors of ... co-Chief Executive Officer and co-President, General Counsel has been ...
Breaking Biology News(10 mins):